Drug intelligence / Profile preview

Dulaglutide Depot

Development stage: Preclinical
Lead developer: Mapi Pharma
Modality: Peptides, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

Dulaglutide Depot is an extended-release formulation of dulaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, developed by Mapi Pharma using its proprietary long-acting depot technology. It is intended for the treatment of diabetes, specifically designed to provide a sustained release of the medication to improve patient compliance and therapeutic outcomes. As a GLP-1 receptor agonist, it enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon secretion, and slows gastric emptying. The product is being developed via the 505(b)(2) regulatory pathway, referencing the approved drug Trulicity.

Other names: Dulaglutide Depot

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on Dulaglutide Depot.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dulaglutide Depot.

Explore the full profile